Brief: Anavex Announces First Entire Clinical Gene Pathway Data Of Anavex®2-73 From Avatar Study In Patients With Rett Syndrome
20/12/2023 12:33
Dec 20 (Reuters) - Anavex Life Sciences Corp AVXL.O :
* ANAVEX ANNOUNCES FIRST ENTIRE CLINICAL GENE PATHWAY DATA
OF
ANAVEX®2-73 FROM AVATAR STUDY IN PATIENTS WITH RETT SYNDROME
Source text for Eikon: ID:nGNX5yMKlH
Further company coverage: AVXL.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Anavex Life Sciences
See all newsBrief: Anavex Provides Corporate Update, Announces Completion Of Clinical Conduct Of Adme And Ddi Clinical Studies
Brief: Anavex Receives FDA Clearance Of Its Ind Application For Blarcamesine In Fragile X Syndrome
Brief: Glass Lewis Recommends Anavex Stockholders To Vote For PVG’s Director Nominees
Brief: PVG Calls For Replacing Anavex Board, Hiring "Experienced" CEO
Brief: Pvg Asset Management- Nominates Six Director Candidates For Anavex Board